Skip to main content
Top
Published in: Journal of Clinical Immunology 1/2011

01-02-2011

Galactosylation of Serum IgA1 O-Glycans in Celiac Disease

Authors: Katri Lindfors, Hitoshi Suzuki, Jan Novak, Pekka Collin, Päivi Saavalainen, Lotta L. E. Koskinen, Markku Mäki, Katri Kaukinen

Published in: Journal of Clinical Immunology | Issue 1/2011

Login to get access

Abstract

In celiac disease, gluten ingestion provokes small-bowel mucosal injury and production of IgA autoantibodies against transglutaminase 2 (TG2). It has been suggested that in celiac patients IgA could mediate the transepithelial passage of gluten peptides in a mechanism involving the transferrin receptor. As IgA1 with galactose-deficient O-linked glycans has elevated affinity for the transferrin receptor, we assessed whether total serum IgA1 and IgA1 anti-TG2 autoantibodies in celiac patients are aberrantly glycosylated. We report that males with celiac disease have higher total serum levels of galactose-deficient IgA1 than non-celiac males. Furthermore, O-glycans of the disease-specific TG2 IgA1 autoantibodies in celiac patients exhibited elevated galactose deficiency. A gluten-free diet had no effect on the total serum levels of galactose-deficient IgA1, whereas the amount of galactose-deficient anti-TG2 IgA1 decreased. Thus, the undergalactosylated IgA1 molecules are not pathognomonic for celiac disease, but galactose deficiency in IgA1 could be an aggravating factor.
Literature
1.
go back to reference Sollid LM. Coeliac disease: dissecting a complex inflammatory disorder. Nat Rev Immunol. 2002;2:647–55.CrossRefPubMed Sollid LM. Coeliac disease: dissecting a complex inflammatory disorder. Nat Rev Immunol. 2002;2:647–55.CrossRefPubMed
2.
go back to reference Heap GA, van Heel DA. Genetics and pathogenesis of coeliac disease. Semin Immunol. 2009;21:346–54.CrossRefPubMed Heap GA, van Heel DA. Genetics and pathogenesis of coeliac disease. Semin Immunol. 2009;21:346–54.CrossRefPubMed
3.
go back to reference Dieterich W, Ehnis T, Bauer M, Donner P, Volta U, Riecken EO, et al. Identification of tissue transglutaminase as the autoantigen of celiac disease. Nat Med. 1997;3:797–801.CrossRefPubMed Dieterich W, Ehnis T, Bauer M, Donner P, Volta U, Riecken EO, et al. Identification of tissue transglutaminase as the autoantigen of celiac disease. Nat Med. 1997;3:797–801.CrossRefPubMed
4.
go back to reference Niveloni S, Sugai E, Cabanne A, Vazquez H, Argonz J, Smecuol E, et al. Antibodies against synthetic deamidated gliadin peptides as predictors of celiac disease: prospective assessment in an adult population with a high pretest probability of disease. Clin Chem. 2007;53:2186–92.CrossRefPubMed Niveloni S, Sugai E, Cabanne A, Vazquez H, Argonz J, Smecuol E, et al. Antibodies against synthetic deamidated gliadin peptides as predictors of celiac disease: prospective assessment in an adult population with a high pretest probability of disease. Clin Chem. 2007;53:2186–92.CrossRefPubMed
5.
go back to reference Kaukinen K, Collin P, Laurila K, Kaartinen T, Partanen J, Mäki M. Resurrection of gliadin antibodies in coeliac disease. deamidated gliadin peptide antibody test provides additional diagnostic benefit. Scand J Gastroenterol. 2007;42:1428–33.CrossRefPubMed Kaukinen K, Collin P, Laurila K, Kaartinen T, Partanen J, Mäki M. Resurrection of gliadin antibodies in coeliac disease. deamidated gliadin peptide antibody test provides additional diagnostic benefit. Scand J Gastroenterol. 2007;42:1428–33.CrossRefPubMed
6.
go back to reference Lindfors K, Mäki M, Kaukinen K. A role for anti-transglutaminase 2 autoantibodies in the pathogenesis of coeliac disease? Amino Acids. 2009;36:685–91.CrossRefPubMed Lindfors K, Mäki M, Kaukinen K. A role for anti-transglutaminase 2 autoantibodies in the pathogenesis of coeliac disease? Amino Acids. 2009;36:685–91.CrossRefPubMed
7.
go back to reference Matysiak-Budnik T, Moura IC, Arcos-Fajardo M, Lebreton C, Ménard S, Candalh C, et al. Secretory IgA mediates retrotranscytosis of intact gliadin peptides via the transferrin receptor in celiac disease. J Exp Med. 2008;205:143–54.CrossRefPubMed Matysiak-Budnik T, Moura IC, Arcos-Fajardo M, Lebreton C, Ménard S, Candalh C, et al. Secretory IgA mediates retrotranscytosis of intact gliadin peptides via the transferrin receptor in celiac disease. J Exp Med. 2008;205:143–54.CrossRefPubMed
8.
9.
go back to reference Collin P, Syrjänen J, Partanen J, Pasternack A, Kaukinen K, Mustonen J. Celiac disease and HLA DQ in patients with IgA nephropathy. Am J Gastroenterol. 2002;97:2572–6.CrossRefPubMed Collin P, Syrjänen J, Partanen J, Pasternack A, Kaukinen K, Mustonen J. Celiac disease and HLA DQ in patients with IgA nephropathy. Am J Gastroenterol. 2002;97:2572–6.CrossRefPubMed
10.
go back to reference Novak J, Julian BA, Tomana M, Mesteck J. Progress in molecular and genetic studies of IgA nephropathy. J Clin Immunol. 2001;21:310–27.CrossRefPubMed Novak J, Julian BA, Tomana M, Mesteck J. Progress in molecular and genetic studies of IgA nephropathy. J Clin Immunol. 2001;21:310–27.CrossRefPubMed
11.
go back to reference Tomana M, Novak J, Julian BA, Matousovic K, Konecny K, Mestecky J. Circulating immune complexes in IgA nephropathy consist of IgA1 with galactose-deficient hinge region and antiglycan antibodies. J Clin Invest. 1999;104:73–81.CrossRefPubMed Tomana M, Novak J, Julian BA, Matousovic K, Konecny K, Mestecky J. Circulating immune complexes in IgA nephropathy consist of IgA1 with galactose-deficient hinge region and antiglycan antibodies. J Clin Invest. 1999;104:73–81.CrossRefPubMed
12.
go back to reference Moura IC, Arcos-Fajardo M, Sadaka C, Leroy V, Benhamou M, Novak J, et al. Glycosylation and size of IgA1 are essential for interaction with mesangial transferrin receptor in IgA nephropathy. J Am Soc Nephrol. 2004;15:622–34.CrossRefPubMed Moura IC, Arcos-Fajardo M, Sadaka C, Leroy V, Benhamou M, Novak J, et al. Glycosylation and size of IgA1 are essential for interaction with mesangial transferrin receptor in IgA nephropathy. J Am Soc Nephrol. 2004;15:622–34.CrossRefPubMed
13.
go back to reference Moldoveanu Z, Wyatt RJ, Lee JY, Tomana M, Julian BA, Mestecky J, et al. Patients with IgA nephropathy have increased serum galactose-deficient IgA1 levels. Kidney Int. 2007;71:1148–54.CrossRefPubMed Moldoveanu Z, Wyatt RJ, Lee JY, Tomana M, Julian BA, Mestecky J, et al. Patients with IgA nephropathy have increased serum galactose-deficient IgA1 levels. Kidney Int. 2007;71:1148–54.CrossRefPubMed
14.
go back to reference Czerkinsky C, Koopman WJ, Jackson S, Collins JE, Crago SS, Schrohenloher RE, et al. Circulating immune complexes and immunoglobulin A rheumatoid factor in patients with mesangial immunoglobulin A nephropathies. J Clin Invest. 1986;77:1931–8.CrossRefPubMed Czerkinsky C, Koopman WJ, Jackson S, Collins JE, Crago SS, Schrohenloher RE, et al. Circulating immune complexes and immunoglobulin A rheumatoid factor in patients with mesangial immunoglobulin A nephropathies. J Clin Invest. 1986;77:1931–8.CrossRefPubMed
15.
go back to reference Coppo R, Basolo B, Piccoli G, Mazzucco G, Bulzomì MR, Roccatello D, et al. IgA1 and IgA2 immune complexes in primary IgA nephropathy and Henoch-Schönlein nephritis. Clin Exp Immunol. 1984;57:583–90.PubMed Coppo R, Basolo B, Piccoli G, Mazzucco G, Bulzomì MR, Roccatello D, et al. IgA1 and IgA2 immune complexes in primary IgA nephropathy and Henoch-Schönlein nephritis. Clin Exp Immunol. 1984;57:583–90.PubMed
16.
go back to reference Schena FP, Pastore A, Ludovico N, Sinico RA, Benuzzi S, Montinaro V. Increased serum levels of IgA1-IgG immune complexes and anti-F(ab’)2 antibodies in patients with primary IgA nephropathy. Clin Exp Immunol. 1989;77:15–20.PubMed Schena FP, Pastore A, Ludovico N, Sinico RA, Benuzzi S, Montinaro V. Increased serum levels of IgA1-IgG immune complexes and anti-F(ab’)2 antibodies in patients with primary IgA nephropathy. Clin Exp Immunol. 1989;77:15–20.PubMed
17.
go back to reference Suzuki H, Moldoveanu Z, Hall S, Brown R, Vu HL, Novak L, et al. IgA1-secreting cell lines from patients with IgA nephropathy produce aberrantly glycosylated IgA1. J Clin Invest. 2008;118:629–39.PubMed Suzuki H, Moldoveanu Z, Hall S, Brown R, Vu HL, Novak L, et al. IgA1-secreting cell lines from patients with IgA nephropathy produce aberrantly glycosylated IgA1. J Clin Invest. 2008;118:629–39.PubMed
18.
go back to reference Cremata JA, Sorell L, Montesino R, Garcia R, Mata M, Cabrera G, et al. Hypogalactosylation of serum IgG in patients with coeliac disease. Clin Exp Immunol. 2003;133:422–9.CrossRefPubMed Cremata JA, Sorell L, Montesino R, Garcia R, Mata M, Cabrera G, et al. Hypogalactosylation of serum IgG in patients with coeliac disease. Clin Exp Immunol. 2003;133:422–9.CrossRefPubMed
19.
go back to reference Holopainen P, Mustalahti K, Uimari P, Collin P, Mäki M, Partanen J. Candidate gene regions and genetic heterogeneity in gluten sensitivity. Gut. 2001;48:696–701.CrossRefPubMed Holopainen P, Mustalahti K, Uimari P, Collin P, Mäki M, Partanen J. Candidate gene regions and genetic heterogeneity in gluten sensitivity. Gut. 2001;48:696–701.CrossRefPubMed
20.
go back to reference Royle L, Roos A, Harvey DJ, Wormald MR, van Gijlswijk-Janssen D, Redwan el-RM, et al. Secretory IgA N- and O-glycans provide a link between the innate and adaptive immune systems. J Biol Chem. 2003;278:20140–53.CrossRefPubMed Royle L, Roos A, Harvey DJ, Wormald MR, van Gijlswijk-Janssen D, Redwan el-RM, et al. Secretory IgA N- and O-glycans provide a link between the innate and adaptive immune systems. J Biol Chem. 2003;278:20140–53.CrossRefPubMed
21.
go back to reference Wold AE, Mestecky J, Svanborg Edén C. Agglutination of E. coli by secretory IgA—a result of interaction between bacterial mannose-specific adhesins and immunoglobulin carbohydrate? Monogr Allergy. 1988;24:307–9.PubMed Wold AE, Mestecky J, Svanborg Edén C. Agglutination of E. coli by secretory IgA—a result of interaction between bacterial mannose-specific adhesins and immunoglobulin carbohydrate? Monogr Allergy. 1988;24:307–9.PubMed
22.
go back to reference Wold AE, Mestecky J, Tomana M, Kobata A, Ohbayashi H, Endo T, et al. Secretory immunoglobulin A carries oligosaccharide receptors for Escherichia coli type 1 fimbrial lectin. Infect Immun. 1990;58:3073–7.PubMed Wold AE, Mestecky J, Tomana M, Kobata A, Ohbayashi H, Endo T, et al. Secretory immunoglobulin A carries oligosaccharide receptors for Escherichia coli type 1 fimbrial lectin. Infect Immun. 1990;58:3073–7.PubMed
23.
go back to reference Mestecky J, Russell MW. Specific antibody activity, glycan heterogeneity and polyreactivity contribute to the protective activity of S-IgA at mucosal surfaces. Immunol Lett. 2009;124:57–62.CrossRefPubMed Mestecky J, Russell MW. Specific antibody activity, glycan heterogeneity and polyreactivity contribute to the protective activity of S-IgA at mucosal surfaces. Immunol Lett. 2009;124:57–62.CrossRefPubMed
24.
go back to reference Forsberg G, Fahlgren A, Hörstedt P, Hammarström S, Hernell O, Hammarström ML. Presence of bacteria and innate immunity of intestinal epithelium in childhood celiac disease. Am J Gastroenterol. 2004;99:894–904.CrossRefPubMed Forsberg G, Fahlgren A, Hörstedt P, Hammarström S, Hernell O, Hammarström ML. Presence of bacteria and innate immunity of intestinal epithelium in childhood celiac disease. Am J Gastroenterol. 2004;99:894–904.CrossRefPubMed
25.
go back to reference Nadal I, Donat E, Ribes-Koninckx C, Calabuig M, Sanz Y. Imbalance in the composition of the duodenal microbiota of children with coeliac disease. J Med Microbiol. 2007;56:1669–74.CrossRefPubMed Nadal I, Donat E, Ribes-Koninckx C, Calabuig M, Sanz Y. Imbalance in the composition of the duodenal microbiota of children with coeliac disease. J Med Microbiol. 2007;56:1669–74.CrossRefPubMed
26.
go back to reference Collado MC, Donat E, Ribes-Koninckx C, Calabuig M, Sanz Y. Specific duodenal and faecal bacterial groups associated with paediatric coeliac disease. J Clin Pathol. 2009;62:264–9.CrossRefPubMed Collado MC, Donat E, Ribes-Koninckx C, Calabuig M, Sanz Y. Specific duodenal and faecal bacterial groups associated with paediatric coeliac disease. J Clin Pathol. 2009;62:264–9.CrossRefPubMed
27.
go back to reference Smith AC, Molyneux K, Feehally J, Barratt J. O-glycosylation of serum IgA1 antibodies against mucosal and systemic antigens in IgA nephropathy. J Am Soc Nephrol. 2006;17:3520–8.CrossRefPubMed Smith AC, Molyneux K, Feehally J, Barratt J. O-glycosylation of serum IgA1 antibodies against mucosal and systemic antigens in IgA nephropathy. J Am Soc Nephrol. 2006;17:3520–8.CrossRefPubMed
28.
go back to reference Gharavi AG, Moldoveanu Z, Wyatt RJ, Barker CV, Woodford SY, Lifton RP, et al. Aberrant IgA1 glycosylation is inherited in familial and sporadic IgA nephropathy. J Am Soc Nephrol. 2008;19:1008–14.CrossRefPubMed Gharavi AG, Moldoveanu Z, Wyatt RJ, Barker CV, Woodford SY, Lifton RP, et al. Aberrant IgA1 glycosylation is inherited in familial and sporadic IgA nephropathy. J Am Soc Nephrol. 2008;19:1008–14.CrossRefPubMed
Metadata
Title
Galactosylation of Serum IgA1 O-Glycans in Celiac Disease
Authors
Katri Lindfors
Hitoshi Suzuki
Jan Novak
Pekka Collin
Päivi Saavalainen
Lotta L. E. Koskinen
Markku Mäki
Katri Kaukinen
Publication date
01-02-2011
Publisher
Springer US
Published in
Journal of Clinical Immunology / Issue 1/2011
Print ISSN: 0271-9142
Electronic ISSN: 1573-2592
DOI
https://doi.org/10.1007/s10875-010-9473-7

Other articles of this Issue 1/2011

Journal of Clinical Immunology 1/2011 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine